2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - R06-R09
Technology and Procedures, Molecular Testing, Bioinformatics, Treatment Considerations, Biological Therapies, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Immunology, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, Study Population, Animal Model
PAPER

989 Circadian disruption impairs CAR-T cell persistence through the BMAL1-TCF7-FOXO1 stemness axis

Wanying Zhang, PhD, Zi Wang2, Zhaozhao Chen3, Heng Mei, MD, PhD4
1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Background

CD19-directed CAR-T cell therapy has transformed the treatment landscape of relapsed/refractory B-cell malignancies. However, limited in vivo expansion, impaired persistence, and progressive functional exhaustion remain major barriers to achieving durable clinical responses. Increasing evidence indicates that the intrinsic cellular state of CAR-T products, particularly the maintenance of stem-like memory programs, critically determines long-term therapeutic efficacy. Although the circadian clock regulates immune cell differentiation, metabolism, and functional homeostasis, whether circadian rhythm disruption (CRD) influences CAR-T cell fate and therapeutic persistence remains largely unknown.

Aims and Methods

This study aimed to determine whether CRD affects CAR-T cell durability and to define the underlying molecular mechanisms. We integrated single-cell transcriptomic datasets from CAR-T products and pre- and post-treatment PBMCs of DLBCL patients receiving CD19 CAR-T therapy. CRD score was established to characterize circadian abnormalities across immune cell populations and evaluate their association with clinical response and CAR-T cell functional states.

To investigate the underlying mechanisms, human CD19 CAR-T cells were subjected to in vitro CRD modeling through repeated phase-shifted serum synchronization, followed by assessment of circadian oscillation, stem-like memory phenotype, proliferation, and antitumor activity, with therapeutic persistence further assessed in xenograft models. Integrated transcriptomic and regulatory analyses were combined with genetic perturbation and rescue experiments to investigate the molecular mechanisms linking circadian disruption to CAR-T-cell dysfunction.

Results

Across multiple stages of CAR-T therapy, elevated circadian disruption was consistently associated with impaired treatment response. Non-responders to CD19 CAR-T therapy exhibited higher CRD scores predominantly within T-cell populations across pretreatment, infusion, and post-treatment stages, suggesting that T-cell intrinsic circadian dysregulation may contribute to CAR-T dysfunction. Analysis of CAR-T infusion products further revealed that CRD-high CAR-T cells displayed a transcriptional state characterized by attenuation of the TCF7-associated stem-like memory program, reduced proliferative capacity, and impaired functional persistence.

Experimental induction of circadian disruption in human CAR-T cells recapitulated these alterations, perturbing core clock gene networks and compromising stem-like memory maintenance, proliferative capacity, and antitumor activity. In xenograft models, CRD-conditioned CAR-T cells exhibited defective in vivo expansion and persistence, resulting in reduced tumor control. Integrative analysis identified TCF7, a central regulator of T-cell stemness, as a key mediator linking circadian disruption to CAR-T dysfunction. TCF7 depletion phenocopied, whereas TCF7 restoration reversed, CRD-induced defects in stemness, proliferation, and antitumor activity. Moreover, TCF7-overexpressing CAR-T cells maintained superior in vivo expansion, persistence, and tumor control under circadian disruption, indicating that restoration of the TCF7 program can alleviate CRD-induced functional decline.

Mechanistically, CRD disrupted BMAL1-dependent regulation of TCF7, with BMAL1 loss impairing and BMAL1 restoration partially rescuing TCF7-dependent CAR-T stemness and function. Consistently, BMAL1-deficient CAR-T cells exhibited impaired in vivo antitumor activity, phenocopying the defects observed in CRD-conditioned CAR-T cells. Downstream analysis of TCF7-regulated transcriptional programs identified FOXO1-associated stemness and survival pathways as potential mediators of CAR-T-cell persistence. Genetic perturbation of FOXO1 demonstrated that FOXO1 is required for TCF7-dependent maintenance of CAR-T-cell persistence and antitumor activity, establishing FOXO1 as a functional downstream effector of the BMAL1-TCF7 regulatory network.

Conclusion

Our study identifies CRD as a determinant of CAR-T persistence and durability. Mechanistically, CRD impairs CAR-T cell fitness through disruption of the BMAL1-TCF7-FOXO1 stemness axis, limiting expansion, persistence, and antitumor activity. These findings highlight circadian optimization as a potential strategy to enhance CAR-T therapeutic efficacy.

Wanying Zhang, PhD: No relevant conflicts of interest to declare.